GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ind-Swift Ltd (BOM:524652) » Definitions » EV-to-EBIT

Ind-Swift (BOM:524652) EV-to-EBIT : 13.46 (As of Jun. 25, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Ind-Swift EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ind-Swift's Enterprise Value is ₹10,689 Mil. Ind-Swift's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹794 Mil. Therefore, Ind-Swift's EV-to-EBIT for today is 13.46.

The historical rank and industry rank for Ind-Swift's EV-to-EBIT or its related term are showing as below:

BOM:524652' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.79   Med: -0.11   Max: 4434.13
Current: 13.47

During the past 13 years, the highest EV-to-EBIT of Ind-Swift was 4434.13. The lowest was -26.79. And the median was -0.11.

BOM:524652's EV-to-EBIT is ranked better than
59.19% of 669 companies
in the Drug Manufacturers industry
Industry Median: 16.85 vs BOM:524652: 13.47

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ind-Swift's Enterprise Value for the quarter that ended in Mar. 2024 was ₹10,500 Mil. Ind-Swift's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹794 Mil. Ind-Swift's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.56%.


Ind-Swift EV-to-EBIT Historical Data

The historical data trend for Ind-Swift's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ind-Swift EV-to-EBIT Chart

Ind-Swift Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.51 46.01 29.72 11.85 13.22

Ind-Swift Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.85 0.65 10.02 1.04 13.22

Competitive Comparison of Ind-Swift's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ind-Swift's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ind-Swift's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ind-Swift's EV-to-EBIT falls into.



Ind-Swift EV-to-EBIT Calculation

Ind-Swift's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10689.378/793.995
=13.46

Ind-Swift's current Enterprise Value is ₹10,689 Mil.
Ind-Swift's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹794 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ind-Swift  (BOM:524652) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ind-Swift's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=793.995/10499.80118
=7.56 %

Ind-Swift's Enterprise Value for the quarter that ended in Mar. 2024 was ₹10,500 Mil.
Ind-Swift's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹794 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ind-Swift EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ind-Swift's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ind-Swift (BOM:524652) Business Description

Traded in Other Exchanges
Address
781, Industrial Area, Phase II, Chandigarh, IND, 160002
Ind-Swift Ltd is an India-based pharmaceutical company. It engages in the manufacturing and marketing of pharmaceutical products. The company's products are classified into divisions namely, Generic Division, NOVA Division, Ethical Division, Nobel Division, Herba Plus Division, Institution Division, and Proposed Division. The manufacturing facilities of the firm are situated in (Derabassi)Punjab, India. Substantial revenue accrues from export sales of products.

Ind-Swift (BOM:524652) Headlines

No Headlines